title: The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitors.
authors.affiliation: Spectrum Pharmaceuticals, 157 Technology Drive, Irvine, CA 92618, USA.
authors.forename: Allen S
authors.initials: AS
authors.lastname: Yang
authors.affiliation: Albert Einstein Academy, 28141 Kelly Johnson Parkway, Santa Clarita, CA 91355, USA.
authors.forename: Brandon J
authors.initials: BJ
authors.lastname: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols; D002986:Clinical Trials as Topic; D019175:DNA Methylation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D044127:Epigenesis, Genetic / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors
keywords: DNA methylation inhibitors; cancer; epigenetic therapy; histone deacetylase inhibitors